Action PV3B EYEPOINT PHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Communiqués EyePoint Pharmaceuticals, Inc. Deutsche Boerse AG

Actions

PV3B

US30233G2093

Temps réel estimé Tradegate
Autres places de cotation
 13:07:51 01/07/2024 		Varia. 5j. Varia. 1 janv.
8,116 EUR +0,25% Graphique intraday de EyePoint Pharmaceuticals, Inc. +3,20% -63,14%
26/06 EyePoint Pharmaceuticals, Inc. met en avant les progrès cliniques et réglementaires de Duravuyu et l'innovation du pipeline lors de la Journée de la R&D 2024 CI
26/06 Transcript : EyePoint Pharmaceuticals, Inc. - Special Call

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
EyePoint Pharmaceuticals to Highlight DURAVYU Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
AQ
EyePoint Pharmaceuticals : R&D Day 2024 Presentation
PU
EyePoint Pharmaceuticals to Highlight DURAVYUTM (vorolanib intravitreal insert) Clinical and Regulatory Progress and Pipeline Innovation at R&D Day 2024
AQ
EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
AQ
EyePoint Pharmaceuticals to Host R&D Day on June 26, 2024
AQ
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
AQ
EyePoint Pharmaceuticals : Goldman Sachs Global Healthcare Conference Presentation
PU
EyePoint Pharmaceuticals to Present at Goldman Sachs 45th Annual Global Healthcare Conference
AQ
EyePoint Pharmaceuticals : Investor Presentation May 2024
PU
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
AQ
EyePoint Pharmaceuticals: Q1 Earnings Snapshot
AQ
EyePoint Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Developments
AQ
EyePoint Pharmaceuticals : PAVIA Topline Data Conference Call Presentation
PU
EyePoint Pharmaceuticals Announces Topline Data from the Phase 2 PAVIA Trial of DURAVYU™ in Non-Proliferative Diabetic Retinopathy
AQ
EyePoint Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(4)
AQ
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
AQ
EyePoint Pharmaceuticals Expands Scientific Advisory Board with World-Renowned Retina Specialists
AQ
EyePoint Pharmaceuticals : Investor Presentation March 2024
PU
EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
AQ
EyePoint Pharmaceuticals: Q4 Earnings Snapshot
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action EYPT
  4. Action PV3B
  5. Actualités EyePoint Pharmaceuticals, Inc.
  6. Communiqués